Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study

Details

• Alternative Title:
  Lancet Infect Dis
• Personal Author:
  Doshi, Reena H ; Mukadi, Patrick K ; Casey, Rebecca M ; Kizito, Gabriel M ; Gao, Hongjiang ; Beatrice, Nguete U ; Laven, Janeen ; Sabi, Lilliane ; Kaba, Didine K ; Muyembe-Tamfum, Jean-Jacques ; Hyde, Terri B ; Ahuka-Mundeke, Steve ; Staples, J Erin
• Description:
  Background
  
  In 2016, outbreaks of yellow fever in Angola and the Democratic Republic of the Congo led to a global vaccine shortage. A fractional dose of 17DD yellow fever vaccine (containing one-fifth [0·1 ml] of the standard dose) was used during a pre-emptive mass campaign in August, 2016, in Kinshasa, Democratic Republic of the Congo among children aged 2 years and older and non-pregnant adults (ie, those aged 18 years and older). 1 year following vaccination, 97% of participants were seropositive; however, the long-term durability of the immune response is unknown. We aimed to conduct a prospective cohort study and invited participants enrolled in the previous evaluation to return 5 years after vaccination to assess durability of the immune response.
  
  Methods
  
  Participants returned to one of six health facilities in Kinshasa in 2021, where study staff collected a brief medical history and blood specimen. We assessed neutralising antibody titres against yellow fever virus using a plaque reduction neutralisation test with a 50% cutoff (PRNT50). Participants with a PRNT50 titre of 10 or higher were considered seropositive. The primary outcome was the proportion of participants seropositive at 5 years.
  
  Findings
  
  Among the 764 participants enrolled, 566 (74%) completed the 5-year visit. 5 years after vaccination, 539 (95·2%, 95% CI 93·2–96·7) participants were seropositive, including 361 (94·3%, 91·5–96·2) of 383 who were seronegative and 178 (97·3%, 93·8–98·8) of 183 who were seropositive at baseline. Geometric mean titres (GMTs) differed significantly across age groups for those who were initially seronegative with the lowest GMT among those aged 2–5 years and highest among those aged 13 years and older.
  
  Interpretation
  
  A fractional dose of the 17DD yellow fever vaccine induced an immunologic response with detectable titres at 5 years among the majority of participants in the Democratic Republic of the Congo. These findings support the use of fractional-dose vaccination for outbreak prevention with the potential for sustained immunity.
  
  Funding
  
  Gavi, the Vaccine Alliance through the CDC Foundation.
  
  
• Subjects:
  Adolescent Adult Antibodies, Neutralizing Antibodies, Viral Child Child, Preschool Democratic Republic Of The Congo Disease Outbreaks Female Humans Male Middle Aged Prospective Studies Vaccination Yellow Fever Yellow Fever Vaccine Yellow Fever Virus Young Adult

  More +
• Source:
  Lancet Infect Dis. 24(6):611-618
• Pubmed ID:
  38335976
• Pubmed Central ID:
  PMC11542170
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  24
• Issue:
  6
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:df6c60313d8fd89ecbc7efefdb8a3b45d966320d3cbeb0f21a61aed257ed83a3ed9950dbea05c597cf3263f7142027339bedbce1b2e688c8a5c55f190d9eb7d0
• Download URL:
  https://stacks.cdc.gov/view/cdc/169964/cdc_169964_DS1.pdf
• File Type:
  [PDF - 271.07 KB ]